Skip to content
Company Analysis

Can-Fite Biopharma Ltd Sponsore CANF

A comprehensive view of key metrics, scores, and financial health for Can-Fite Biopharma Ltd Sponsore

Overview of Can-Fite BioPharma Ltd.

CANF ASE
Healthcare Biotechnology Micro Cap
Can-Fite BioPharma Ltd. (CANF), is a Micro Cap company, in the Biotechnology industry, last closed at $3.60, about 0.0% overvalued vs fair value, -89.1% 1Y return, ranked 814/1110 in sector.
$3.60
-3.23%
As of March 13, 2026
Previous close • Vol 90d: 119.9%
52-Week Range
Market Cap
$4.71M
Enterprise Value
$-1.65M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Can-Fite Biopharma Ltd Sponsore.

Top Beats
No strong beats yet

Quick Facts

Website https://www.canfite.com
HQ Ramat Gan
Employees 5
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-9
$-9
$-9
Current: $3.60

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$4.8M
12.8%%
Total Revenue
$674.0K
-9.3%%
Net Income
$-7.9M
-3.2%%
Operating Expense
$8.8M
-1.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
7.6 months
Poor

Critical: Cash runway under 12 months

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$2.6M
53.7% of Cash on Hand

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Can-Fite Biopharma Ltd Sponsore's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
66
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing CANF's balance between Growth (17.9%), Profitability (30.4%), and Safety (51.8%). Growth 18% Safety 52% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

19th percentile vs peers
20
Key Signals
TSR -97.4% 19p
Strengths
  • Cash To Debt Ratio in top 20% of peers (46.39, 84th percentile)
Risks
  • Growth in bottom 20% of peers (percentile: 19)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

56th percentile vs peers
57
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Can-Fite Biopharma Ltd Sponsore.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-8.65
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info